OBJECTIVES: Intravenous immunoglobulins have been shown to be effectiv
e in the treatment of immunologically mediated thrombocytopenia, Sever
al articles have been published on the positive effect of immunoglobul
ins in sepsis-related death. We retrospectively studied the effect of
intravenous immunoglobulins used during septic shock thrombocytopenia
over a 5 year period in a polyvalent intensive care unit PATIENTS AND
METHODS: Inclusion criteria were development of acute thrombocytopenia
under 75 G/I during. septic shock, excluding all cases of disseminate
d intravascular coagulation. Thirty-five patients were included in the
study; 18 were given polyvalent intravenous immunoglobulins (group Ig
IV) and 17 were not (controls). The two groups were comparable for SAP
S and APACHE II gravity scores at admission and at day 0 (first day of
septic shock with platelet count under 75 G/I), age, sex. platelet co
unt at admission, OSF score, type of referral unit, McCabe score. and
the presence of 4 parameters which might affect platelet count: hemofi
ltration, ARDS, surgery, Swan-fanz catheter. RESULTS: Platelet counts
increased on day 8 in the treatment, group (63.5 G/I, range 25-453 ver
sus 105.7 G/I, range 38-355; p = 0.0505). The number of days with thro
mbocytopenia was the same in both groups. Overall mortality was high (
60%) but there was a difference between the two groups in favor of the
treated group (74.7%) versus 44.4%; p = 0.053). The number of red cel
l units (214 vs. 164) and plasma units (175 vs. 54) transfused was hig
her in the control group. Platelet transfusion was equivalent in the t
wo groups. DISCUSSION: Although we were unable to demonstrate a signif
icant difference in the effects of immunoglobulins on platelet level a
nd mortality the trend during this evaluation was comparable with that
reported in the literature I For transfusion, and although the result
s. were not significant, a notion of reduced risk was evident Prospect
ive trials are needed to confirm these observations.